Business Context and Reporting Period
This Form 8-K, filed by Deep Medicine Acquisition Corp. (DMAQ) on January 25, 2024, reports the results of its January 19, 2024 special stockholder meeting concerning the proposed business combination with TruGolf Holdings, Inc. The filing is not an operating-period financial report.
Key Financial Metrics and Liquidity
- 378,744 public shares were redeemed.
- $4,355,556, or approximately $11.50 per share, is expected to be withdrawn from DMAQ’s trust account to fund the redemptions.
- The filing does not provide revenue, profit, cash flow, margin, debt, or post-redemption cash balance information.
Material Changes and Transaction Status
Stockholders approved all proposals presented at the special meeting, including the business combination, amendments to the charter, governance proposals, the equity incentive plan, director elections, and the Nasdaq listing proposal.
| Proposal | For | Against | Abstain | Broker Non-Votes |
|---|---|---|---|---|
| NTA proposal | 3,952,776 | 200 | 3 | 0 |
| Business combination | 3,933,438 | 18,838 | 703 | 0 |
| Charter proposal | 3,933,938 | 18,838 | 203 | 0 |
| Governance proposals 4A–4E | 3,933,840–3,933,941 | 18,838 | 200–203 | 0–101 |
| Equity incentive plan | 3,933,840 | 18,838 | 200 | 101 |
| Director election | 3,933,837 per nominee | 19,038 withheld per nominee | — | 104 per nominee |
| Nasdaq proposal | 3,933,837 | 18,838 | 203 | 101 |
Because sufficient votes were received, the adjournment proposal was not presented. DMAQ expected to close the business combination after satisfying or waiving the merger agreement’s conditions, including Nasdaq approval.
Outlook, Risks, and Unusual Items
- DMAQ scheduled another special meeting for January 26, 2024 to consider extending the business-combination deadline from January 29, 2024 to July 29, 2024.
- Completion remained subject to closing conditions and was not guaranteed.
- Key risks include failure or delay of the transaction, termination of the merger agreement, litigation, inability to realize anticipated benefits, redemption levels, insufficient or uncertain financial information, and risks relating to TruGolf’s financial condition, liquidity, operations, market opportunity, and projected performance.
- The filing contains forward-looking statements and states that actual results may differ materially; neither DMAQ nor TruGolf assumed an obligation to update those statements.
Investor Verification Checklist
- Verify whether the business combination was ultimately completed and the date and terms of closing.
- Verify the outcome of the January 26, 2024 extension vote and any subsequent deadline extensions.
- Confirm the final post-redemption trust-account balance, capital structure, and financing arrangements.
- Review the definitive proxy statement/prospectus for TruGolf’s historical financial statements, projections, valuation, risk factors, and merger conditions.
- Confirm Nasdaq listing approval and the combined company’s final trading symbol and governance structure.